BEXIMCO PHARMACEUTICALS LTD.

News Release

15th July 2011

Beximco Pharma introduces Ribox-120

Leading drug manufacturer Beximco Pharmaceuticals Ltd (BPL) has introduced new strength of etoricoxib, Ribox-120, for the management of pain associated with ankylosing spondylitis, acute gouty arthritis & dental procedure.

Ribox-120 is preparation of Etoricoxib 120mg. Etoricoxib is a COX-2 selective inhibitor (approx. 106.0 times more selective for COX-2 inhibition over COX-1). Ribox-120 is indicated for the symptomatic relief of ankylosing spondylitis, the pain and signs of inflammation associated with acute gouty arthritis and dental pain. As etoricoxib is a selective COX-2 inhibitor so it only act on pain & inflammation without interfering COX-1 mediated gastro protective functions. As a result, Ribox reduce pain & inflammation with better GI safety. Besides this Beximco Pharma already launched Ribox-60 & Ribox-90.

Research & Development

Research & Development

 

Our product development team continues its strong research orientation in formulation development to transform BPL into a truly international one.

 Read More

Manufacturing Facilities

Manufacturing Facilities

 

Beximco Pharmaceuticals Ltd. (Beximco Pharma) is a leading manufacturer of medicines and active pharmaceutical ingredients (APIs) based in Bangladesh.

 Read More

Corporate Responsibility

Corporate Social Responsibility

 

CSR initiatives are an integral part of our strategic commitment, and we are always guided by strong ethical values to operate responsibly within broader social and economic context.

 Read More

Health & Wellness

Health & Wellness

 

Life's all about staying healthy and enjoying the good things in life! However, illness is inevitable at all stages of life. In this area learn about the common health problems.

 Read More

Our Product

  • All
  • Allergic Disorders
  • Analgesics & Antipyretic
  • Anti–infectives
  • Cardiovascular
  • Central Nervous System
  • Cough & Cold
  • Endocrine & Diabetes
  • Eye Care
  • Gastrointestinal
  • Hormones & Steroid
  • Intravenous Fluids
  • Muscloskeletal
  • Oncology
  • Other Products
  • Respiratory
  • Skin Care
  • Vitamins & Minerals Supplement
load more hold SHIFT key to load all

Global Footprint

Beximco Pharma has so far exported medicines to more than 40 countries around the world.

 Read More

Contract Manufacturing Opportunities

Rising cost of healthcare and medicines has become a global concern, and in order to reduce cost across the value chain, pharmaceutical companies from developed markets.

 Read More

Our People

We believe, our dedicated and highly skilled people – their collective resolve to excel- have always guided us towards newer achievements and set a course for the bright future.

 Read More

Investor Relations

This section of our website contains essential information on Beximco Pharmaceuticals Ltd. You can view and download our financial reports and keep up to-date with the latest news and company information.

 Read More

Winner

  • invima
  • Asaia most promising brand

 

 

  • FDA Export

Certified

  • TGA
  • AGES
  • GCC
  • TFDA
  • ANVISA
  • Health Canada